Fuisz Announces Further Advances in Drug Compliance Verification for Opioids
MIAMI, Sept. 21 /PRNewswire-USNewswire/ — Fuisz Pharma (www.fuisz.com) today announced several advances in pharmaceutical compliance diagnostic systems, primarily directed at Opioids but also applicable to other drug classes.
First, Fuisz placed its recent acquisition of the dominant, issued patent concerning the use of dyes and stains to demonstrate opioid misuse, within the larger context of Fuisz’s compliance system. Fuisz calls this system Closed Loop Diagnostic System (CLDS).
Fuisz Pharma’s Managing Member, Joseph Matus Fuisz, explained: “Our primary concern is the demonstration of compliant, and alternatively non-compliant, use of an opioid. To this end, we include in the dosage form or in other ways a GRAS Trojan Agent. The Trojan Agent is selected to be readily identifiable – in the compliant patient and in the abuser, whether on the nasal mucosa when snorted, in the urine when excreted, on the oral mucosa for orally dissolving dosage units or in other ways. By placing the Trojan Agent in the loop and then looking for its presence, we confirm compliant and non compliant use of Opioids – hence the term Closed Loop Diagnostic System (CLDS). The simultaneous use of multiple Trojan Agents with different attributes provides a robust level of detection capability that is readily usable by the physician. This functions as an immediate diagnostic system without the use of reagents. The availability of objective detection techniques are welcomed by physicians who currently bear a difficult burden under REMS systems to look for subjective criteria of abuse. This system is protected by one issued patent and numerous patents pending.”
“In addition, we cannot state more simply the philosophy that most abuse grows from the seed of non compliance. It is shortsighted to not understand this. Compliance observed and confirmed is King here. However, our CLDS system evidences abuse as well. This has great value to emergency care apart from REMS issues.”
Secondly, Fuisz Pharma announces further advances in its delivery system for augmenting or retarding the absorption of bioactives as well as opiate paired antagonists. Joseph Matus Fuisz commented, ” This system is just scientifically elegant. It evolves and improves existing formulations with the simplicity of a Swiss Army Knife. If you are a Pharma company, you are either already a client or you should be a client. As usual at Fuisz, there is abundant filed IP behind our systems.
Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma. Fuisz Pharma has its headquarters in Miami. www.fuisz.com.
SOURCE Fuisz Pharma